Authors
Arjun Seth, Jeffrey A Allen
Published in
Continuum (Minneapolis, Minn.). Volume 32. Issue 5. Pages 1416-1439. Epub Oct 02, 2026.
Abstract
This article describes the cardinal clinical, electrophysiologic, and supportive features of typical CIDP and its variants, how to review and apply CIDP diagnostic criteria, objective measures that can be used in practice to follow patients with CIDP, and current and emerging treatment practices.
The diagnostic criteria for CIDP have been simplified to a diagnosis of either CIDP or possible CIDP. Chronic inflammatory sensory polyradiculoneuropathy is no longer considered a variant of CIDP. Autoimmune nodopathies are considered a separate entity with some clinical and electrodiagnostic features similar to CIDP. Treatments include IV immunoglobulin (IVIg), subcutaneous immunoglobulin, corticosteroids, and plasmapheresis. Subcutaneous efgartigimod alfa, a neonatal Fc-receptor antagonist, was approved by the US Food and Drug Administration (FDA) in June 2024 for the treatment of CIDP, the first novel treatment by drug class for this condition. Complement inhibition is currently being explored in clinical trials for the treatment of CIDP.
CIDP is a rare, treatable neuropathy that is frequently misdiagnosed. As novel therapeutics are studied and approved for clinical use, special attention to the diagnostic criteria and the use of objective treatment outcome measures are essential to preventing misdiagnosis and ensuring that patients receive appropriate therapies.
PMID:
42825557
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 13
- Comments 0